Centro Escolar University

Department of Nursing

The Use of Hera-Mi as CDSS Tool

In partial requirement of Nursing informatics (NCM 110)
S.Y. 2021-20212

Submitted By:

Group 10
Bernardo, Matthieu
Casaclang, Mary Angel
Maglalang, Clarissa
Oliveros, John Mervin
Ramos, Aureli
Santos, Kathleen Marie T.
Group 10

BSN3A
 HERA-MI

Introduction

The advancement of technology has brought various innovations and different

applications in shaping our daily lives, especially in the healthcare industry. One of which is the
use of a clinical decision support system or CDSS as a tool for information management;
countless diseases require a lot of research and study for efficient treatment and successful
elimination of it. However, this tool speeds up the process as it is deemed to be the most
important diagnostic technology used to aid healthcare professionals in analyzing patients’ data
and formulating a diagnosis to achieve quality care for patients.

Hera-Mi is one of the CDSS tools developed in detecting early-stage breast cancer and
improves its diagnosis in less time. We all know that cancer is a life-threatening disease that can
develop at any age. In the Philippines, 26 females out of 100 females and 1 male for every 105
males may be diagnosed with breast cancer. Thus, Since the 1980s, breast cancer ranks 1st
among the top leading cancers afflicting women in the Philippines. Its incidence starts to peak at
the age of 30 in women (Philippine Cancer Facts & Estimates, PCSI, 2005).

Therefore, with this innovation developed- the Hera-Mi, we can easily detect breast
cancer and reduce women’s prevalence and incidence of this deadly disease. This paper will
introduce you to this CDSS tool.

History and Background

Hera-MI is a French corporation based in Nantes. Its name is derived from Greek
mythology, “Hera”, the protective goddess of women, life, and family, and “MI” stands for
Medical Imaging. The person behind this innovation is Ms. Sylvie Davila, who holds a Ph.D. in
Biology and an Executive MBA from Audencia Business School which launched the company in
April 2017.

Hera-MI, a company that specializes in digital medical imaging for breast cancer which
created clinical decision support systems to aid enhance early-stage breast cancer detection.
These technologies improve the quality and accuracy of a breast cancer diagnosis while saving
physicians time. Therefore, patients will be treated faster to give them a better chance of
remission.
 Hera-MI has become the first and only French firm to acquire CE mark clearance for a
clinical decision support software in 2D and 3D mammography based on Artificial Intelligence
since November 2019.

Information overload is a problem radiologists experience due to a large number of

images they need to deal with daily. That huge amount of data exceeds the capacity of the human
brain. This causes intense stress and fatigue which can negatively affect the radiologist's quality
of diagnosis. Considering those issues, the major objective is to employ artificial intelligence to
aid in the early detection of breast cancer. AI can evaluate a large amount of data in a short
amount of time. The AI would also be useful in detecting anomalies that sometimes are
overlooked.

Description of CDSS Tool

Hera-MI is a tool Specialized in digital medical imaging for breast cancer. It utilizes
Artificial Intelligence (AI) to analyze images vertiginously fast, detect abnormalities that are
hard to see for radiologists, and aid them to detect early stages of breast cancer for their
diagnosis. This results in faster development of patient care, thus saving millions of women's
lives around the globe.

The intention of this CDSS tool is to accelerate and improve breast cancer diagnosis
through clinical decision support solutions. This will enable healthcare professionals to reduce
the time they spend on non-problematic cases and spend extra time on more complex ones. Thus,
aid physicians to focus on their core business, which is their added value, the analysis of
potentially suspicious areas.

Clinical activities and features of Hera-Mi

Over the past few years, the volume of medical images has been constantly expanding
and generates 1,000 to 1,500 images per medical exam, which is 40 times more than 30 years
ago. The surge of a huge amount of data can potentially result in a less efficient diagnosis due to
the intense stress and fatigue of healthcare professionals. With this, Hera-MI has developed a
patented technology for 2D/3D mammography called Breast-SlimView made for clinical
decision assistance.

Breast-SlimView is a unique and interruptive reading aid where only pertinent

information is shown. This offers healthcare professionals the opportunity to reduce irrelevant
information and visualize at a glance the potential suspicious areas. Breast-SlimView will enable
radiologists to decrease the time they spend on non-problematic cases and spend extra time on
more complex ones. Hera-MI will help radiologists focus on their core business, which is their
added value, the analysis of potentially suspicious areas.

The "Negativation" is the technical procedure of the patent (masking of healthy areas of
the breast). In fact, all-normal physiological regions (vessels, glandular tissue, fatty tissue, and
mammary gland) are automatically detected and removed by Breast-SlimView, and replaced with
fake fate. Based on technical innovation, the company incorporates a number of new features
such as an instructive 2D/3D image analysis tool and a unique help for reading for diagnostics.

In this context, the feature of this CDSS tool aids both patients and physicians to help
promote the early diagnosis of breast cancer, analyze a huge quantity of data in a very short time,
and help detect anomalies that can be sometimes hard to see.

Issues and concerns in the use or application of the CDSS tool

Breast cancer often starts out too small to be felt. As it grows, it can spread throughout
the breast or to other parts of the body. This causes serious health problems and can cause death.

It is limited to countries that are able to utilize it since it is only available in Europe,
North Africa and the Middle East, the only drawback of it. Only a few institutions then
implement this, which implies there is still no substantial reduction in the elimination and
diagnosis of breast cancer. With the help of the Hera Mi, it can diagnose the early signs of breast
cancer. The scarcity of the product is one of the concerns that the medical field will face in the
future.

Analysis & Conclusion:

The best way to fight against breast cancer is to detect it early. Indeed, when breast cancer
is detected at an early stage, nearly 90% of cases go into remission. Radiologists will be able to
free themselves from overloaded information and visualize potentially suspicious areas at a
glance. The patent is based on mammography exams negation. The scarcity of the product limits
what the product can do for the community. Availability of this product can bring a huge impact
to the community with regards to diagnosing breast cancer.

The availability of the product for mass use does not contribute well to its own ambitions
which is to optimize patient care of millions of women worldwide. In the future, Hera-MI plans
to develop and adjust Breast-SlimView to be used for other types of cancer such as lung cancer,
prostate cancer and colorectal cancer. Hera-mi CDSs might, in particular, enhance health care
services for patients, time for decision-making and health-related quality of life and reduce
healthcare expenditures and the incidence of medical errors.
References
​

Anwar, S. M., & Bagci, U. (2019). Artificial intelligence as another set of eyes in breast cancer
diagnosis. Journal of Medical Artificial Intelligence, 2, 10.
https://doi.org/10.21037/jmai.2019.04.03

Hera-MI launches subsidiary in the United States. (2020, June 11). Atlanpole Biotherapies.
https://www.atlanpolebiotherapies.eu/news/hera-mi-launches-subsidiary-in-the-united-states/

Hera-Mi. (n.d.). Breast-SlimView. https://www.hera-mi.com/en/breastslimview/. Retrieved

August 24, 2021, from https://www.hera-mi.com/en/breastslimview/

Chilard, V. (n.d.). HERA-MI: Artificial Intelligence for early stage breast cancer diagnosis.

Centrale Nantes. Retrieved August 24, 2021, from

https://www.ec-nantes.fr/innovation/incubator-and-startups/hera-mi-artificial-intelligence-for-ear

ly-stage-breast-cancer-diagnosis#:~:text=Hera%2DMI%20aims%20to%20use

Argenal, R., Baterna, M., Peña, C., Ravina, J., & Sionzon, M. (2019). RISK FACTORS OF

BREAST CANCER AMONG WOMEN: A META ANALYSES .

https://psa.gov.ph/sites/default/files/4.2.2%20Risk%20Factors%20of%20Breast%20Canc

er%20among%20Women%20A%20Meta%20Analysis.pdf

Charles, M. (2018). Clinical decision support system (CDSS). SearchHealthIT.

https://searchhealthit.techtarget.com/definition/clinical-decision-support-system-CDSS#:

~:text=A%20clinical%20decision%20support%20system
Chilard, V. (2020, January 9). HERA-MI: Artificial Intelligence for early stage breast cancer

diagnosis. Centrale Nantes.

https://www.ec-nantes.fr/innovation/incubator-and-startups/hera-mi-artificial-intelligence

-for-early-stage-breast-cancer-diagnosis

Hera-Mi. (n.d.). Hera-MI - About us. Www.hera-Mi.com. Retrieved August 25, 2021, from

https://www.hera-mi.com/en/about-us/

Atlanpolebiotherapies. (2019, November 28). Hera-MI receives EC Mark Approval for its

software, Breast-SlimView, for 2D & 3D Mammography.

https://www.atlanpolebiotherapies.eu/news/hera-mi-receives-ec-mark-approval-for-its-software-

breast-slimview-for-2d-3d-mammography/